Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes
In a contemporary Swiss cohort of patients with ACS, up to 32 % would be eligible for omega-3 FA-EPA supplementation one year after ACS, highlighting an opportunity to mitigate residual cardiovascular risk in patients with ACS and hypertriglyceridemia.
Authors
- Nicolas Rodondi (ORCID: https://orcid.org/0000-0001-9083-6896)
- David Nanchen (ORCID: https://orcid.org/0000-0002-2493-3505)
- Christian M. Matter (ORCID: https://orcid.org/0000-0002-8124-1767)
- David Carballo (ORCID: https://orcid.org/0000-0003-3212-1272)
- Cédric Follonier (ORCID: https://orcid.org/0000-0001-6848-4978)
- Stephan Windecker (ORCID: https://orcid.org/0000-0003-2653-6762)
- Roland Klingenberg (ORCID: https://orcid.org/0000-0002-7726-4421)
- Moa Lina Haller (ORCID: https://orcid.org/0009-0006-2380-349X)
- Sebastian Carballo (ORCID: https://orcid.org/0000-0002-8344-4293)
- Bariş Gencer (ORCID: https://orcid.org/0000-0002-8954-9694)
- Mattia Branca
- Konstantinos C. Koskinas (ORCID: https://orcid.org/0000-0002-5589-7762)
- Dik Heg
- Gabriel Rabassa
- François Mach (ORCID: https://orcid.org/0009-0004-0364-1070)
- Lorenz Räber
Institutions
- University of Geneva (CH)
- University of Bern (CH)
- University of Zurich (CH)
- University Hospital of Bern (CH)
- University Hospital of Geneva (CH)
- Centre universitaire de médecine générale et santé publique, Lausanne (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Atherosclerosis Plus
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1016/j.athplu.2024.09.002
- Citations
- 2
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 0.62
Funders
- Eli Lilly and Company
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- St. Jude Medical